New drug combo aims to outsmart aggressive colon cancer
NCT ID NCT07412613
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial is testing whether adding the immunotherapy drug AK104 (cadonilimab) before and after surgery can improve outcomes for people with a specific type of colon cancer (MSI-H/dMMR). About 386 participants will be randomly assigned to receive either AK104 plus standard chemotherapy or chemotherapy alone. The main goals are to see if the cancer disappears completely after treatment and if it delays the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cadonilimab (AK104), a drug that helps the immune system fight cancer, plus standard chemotherapy drugs (oxaliplatin, capecitabine, 5-fluorouracil, calcium folinate)
What this could lead to
If this works, it could offer a more effective treatment option for people with a specific type of colon cancer, potentially reducing the chance of cancer coming back after surgery.
What could go wrong
This is an early-phase 3 trial, so results are not yet known. The new drug may not work better than standard chemo, and it could cause side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••